Navigation Links
Biopure Seeks Compassionate Use Protocol for Treatment of Acute Anemia
Date:8/23/2007

CAMBRIDGE, Mass., Aug. 23 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) today announced that the company submitted a draft clinical study protocol to the FDA for compassionate use of the investigational product Hemopure (HBOC-201) in the United States. The proposed open label study would make Hemopure available to patients for the treatment of life threatening or potentially life threatening anemia on a compassionate use basis where blood transfusion is not an option.

The product has been available for compassionate use since December 2006. Under the existing program the company evaluates individual requests from treating physicians for specific patients. If the patient is deemed an appropriate candidate for treatment, the FDA is contacted and a single patient IND is requested. To date the FDA has authorized shipment of Hemopure for 20 patients. Of the treated patients, four were experiencing severe anemia secondary to the management and treatment of leukemia and lymphoma. The balance of the compassionate use cases were for the treatment of blood loss resulting from surgical complications or trauma. The remaining patients who were not treated stabilized at the site by the time the drug was received.

The draft protocol outlines general eligibility criteria that include the following:

-- Severe, life threatening, or potentially life threatening anemia

-- Blood transfusion is not feasible

-- All alternative treatment options have been exhausted

-- Adult male or female - 18 years of age, or child with anemia secondary

to severe burns

The safety, efficacy and pharmacology of Hemopure have been studied in 22 completed clinical trials. An additional four trial
'/>"/>

SOURCE Biopure Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Point of Care Strep Tests Speed Treatment, Lower Costs
2. Rapid HIV Testing Increases Possibility of Treatment
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
9. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
10. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
11. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014  For Cloud ... drug design and development, partnering is an integral ... is to design new drugs and identify early ... partners to further their development. The company also ... To support this business model, Cloud Pharmaceuticals will ...
(Date:9/19/2014)... Sept. 19, 2014  Diplomat, the nation,s largest independent ... Dreyer to the Board of Directors on September ... will also serve as chair of the Audit Committee. ... of accounting, financial, compliance and operating experience in the ... served as chief financial officer, chief operating officer and ...
(Date:9/19/2014)... -- Alere Inc. (NYSE: ALR ), a global ... in support of President Barack Obama,s Executive ... leader in rapid diagnostics for infectious disease, we commend ... the serious threat of antibiotic resistance. We look forward ... to promote the development of rapid point-of-care tests that, ...
Breaking Medicine Technology:Cloud Pharmaceuticals Announces Partnering Sessions and Presentation Schedule 2David Dreyer Appointed to Diplomat Board of Directors 2Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2
... 19, 2011 MMIS , Inc. ... compliance solutions for the life science industry, announced the ... aggregate spend reporting solution, at the ExL Pharma 2nd ... MediSpend™ allows pharmaceutical, medical device and biotechnologies companies to ...
... Health today announced a joint venture with leading China ... to doctors in China as the country prepares for ... Wolters Kluwer Health to expand its market-leading Clinical Decision ... growing China market and creates a needed drug information ...
Cached Medicine Technology:MMIS, Inc. Launches the MediSpend™ Aggregate Spend Solution 2Wolters Kluwer Health Enters Joint Venture with China Drug Information Provider Medicom 2Wolters Kluwer Health Enters Joint Venture with China Drug Information Provider Medicom 3
(Date:9/19/2014)... 19, 2014 Singulair, developed by Merck, ... of leukotriene D4 (LTD4). LTD4 belongs to the family ... of cells, including mast cells and eosinophils, and which ... have determined that there are higher concentrations of Cys-LTs ... non-asthmatic individuals. The production of CysLTs is increased in ...
(Date:9/19/2014)... University researchers say a simple test that combines ... risk for developing Alzheimer,s disease in a person, ... of dementia., Faculty of Health Professor Lauren Sergio ... study asked the participants to complete four increasingly ... laptop computers. The test aimed at detecting the ...
(Date:9/19/2014)... September 19, 2014 The ... traditional Scandinavian style of eating, is making ... like Diet Doc’s medical weight loss ... and eating good food which leads to ... on teaching patients to understand how diet ...
(Date:9/19/2014)... September 19, 2014 2013 NEXT ... named a finalist for the 2014 NEXT Awards ... president Tammy Hawes has been selected as the ... The Nashville Area Chamber of Commerce and the ... to recognize the accomplishments of companies and individual ...
(Date:9/19/2014)... King of Prussia, PA (PRWEB) September 19, 2014 ... provider of Business Process Outsourcing solutions for Health ... and Managed Medicaid markets, will sponsor a Networking ... Director in the Health Industry Advisory Practice at ... 30, 2014 at the AHIP’s 2014 National Conference ...
Breaking Medicine News(10 mins):Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 2Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 3Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 4Health News:Simple test can help detect Alzheimer's before dementia signs show: York U study 2Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 2Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 3Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 4Health News:Virsys12 and Founder Tammy Hawes Each Named 2014 NEXT Awards Finalists 2Health News:Virsys12 and Founder Tammy Hawes Each Named 2014 NEXT Awards Finalists 3Health News:TMG Health To Sponsor Pricewaterhouse Coopers Speaker at AHIP’s National Conference on Medicare 2Health News:TMG Health To Sponsor Pricewaterhouse Coopers Speaker at AHIP’s National Conference on Medicare 3
... /PRNewswire-FirstCall/ Medizone International,Inc. (Pink Sheets: MZEI) announces ... TDV Global, Inc. (TDVGlobal.com). TDV Global,is a ... Approximately 70% of their business involves consulting ... private enterprise,mostly in the Health and Security ...
... 4 Senesco,Technologies, Inc. ("Senesco" or the "Company") ... will be presenting at the 10th Annual,Rodman & ... the New York,Palace Hotel from November 10-12, 2008. ... will deliver the Company,s corporate,presentation on Tuesday, November ...
... WELLINGTON, Fla., Nov. 4 The Quantum Group,Inc. ... healthcare organization,announced today that Noel J. Guillama, President ... Investment,s 31st Annual Westergaard,Conference on November 12, 2008. ... Vice President and Chief Technology & Innovations Officer,and ...
... and Conference Call ... 8%, HAYWARD, Calif., Nov. 4 Thermage, Inc.,(Nasdaq: ... third quarter,ended September 30, 2008 for both Thermage and ... it may update its Form,S-4 filing with the Securities ...
... connects employers and candidates faster, brings unprecedented functionality and ease of ... ... 4, 2008 -- Dayak, the leading online recruiting marketplace ... easier, and more efficiently, today launched a new version of its ...
... for the Achievement,of Human Potential (IAHP) announced today that ... on The Institutes, world,headquarters in Wyndmoor, Pennsylvania on December ... Child" -- an intensive course covering every,aspect of special ... child who is almost normal but not quite., ...
Cached Medicine News:Health News:Medizone International, Inc. Announces Strategic Consulting Relationship With TDV Global, Inc. 2Health News:Senesco Technologies to Present at 10th Annual Rodman & Renshaw Healthcare Conference 2Health News:Senesco Technologies to Present at 10th Annual Rodman & Renshaw Healthcare Conference 3Health News:The Quantum Group Inc. To Present at Paulson Investment's 31st Annual Westergaard Conference 2Health News:The Quantum Group Inc. To Present at Paulson Investment's 31st Annual Westergaard Conference 3Health News:Thermage Discloses Preliminary 3Q 2008 Results for Thermage and Reliant 2Health News:Thermage Discloses Preliminary 3Q 2008 Results for Thermage and Reliant 3Health News:Thermage Discloses Preliminary 3Q 2008 Results for Thermage and Reliant 4Health News:Dayak Makes Hiring Even Easier, Unveils New Version Of Web Interface For Employers 2Health News:Dayak Makes Hiring Even Easier, Unveils New Version Of Web Interface For Employers 3Health News:Parenting Course at The Institutes for the Achievement of Human Potential Gives Parents the Tools to Help their Special Needs Kids Have a Fighting Chance 2
... Volks revolutionary MiniQuad, the DynaView 156 is ... of the retina extending to the ora ... patients. Featuring a minified housing and reduced ... revolutionizes retinopathy of prematurity surgery and is ...
... If you prefer a standard ... the Volk Iridectomy Lens. Its ... view you're used to but ... Volk's exclusive Double Aspheric design ...
... re-designed Super Macula® 2.2 offers extremely high ... fovea, while achieving an exceptionally wide 78° ... excellent choice for critical evaluation of the ... for detailed views of the macula and ...
... The Volk TransEquator is designed for ... diagnosis. Its unique optical design presents a ... an impressive wide-field view of the entire ... superior optics of this lens allows dynamic ...
Medicine Products: